Table 4.

(A) Female Sexual Function Index (FSFI) and (B) Female Sexual Distress Scale (FSDS) intragroup and intergroup comparison of women with endometriosis-associated pain symptoms at baseline and at 3, 6 and 12 months of 24/4 regimen 17β-estradiol (1.5 mg) and Nomegestrol Acetate (2.5 mg) (E2/NOMAC) combined oral contraceptive, or of Dienogest (DNG) 2 mg daily

FSFI score	Baseline	3rd month follow-up	6th month follow-up	12th month follow-up	p
A
E2/NOMAC Group	20.8 ± 1.9	27.5 ± 1.6	28.6 ± 2.5	30.2 ± 2.8	< 0.001
DNG Group	21.1 ± 1.2	27.8 ± 1.3	29.7 ± 2.9	31.3 ± 2.7	< 0.001
p	0.18 95% CI − 0.7 to 0.1	0.15 95% CI − 0.7 to 0.1	0.005 95% CI − 1.8 to − 0.3	0.006 95% CI − 1.8 to − 0.3

FSDS score	Baseline	3rd month follow-up	6th month follow-up	12th-month follow-up	p
B
E2/NOMAC Group	18.5 ± 1.5	13.6 ± 1.7	10.2 ± 1.8	10 ± 1.4	< 0.001
DNG Group	18.4 ± 1.3	11.3 ± 1.4	10.1 ± 1.6	9.8 ± 1.5	< 0.001
p	0.6 95% CI − 0.3 to 0.5	< 0.001 95% CI 1.8 to 2	0.68 95% CI − 0.4 to 0.6	0.33 95% CI − 0.2 to 0–6